Why proteasome inhibitors cannot ERADicate multiple myeloma

Cancer Cell. 2013 Sep 9;24(3):275-7. doi: 10.1016/j.ccr.2013.08.014.

Abstract

Proteasome inhibitors are key parts of our armamentarium against multiple myeloma, but the disease can become resistant through poorly defined mechanisms. In this issue of Cancer Cell, Leung-Hagesteijn and colleagues describe XBP1s(-) subpopulations of tumor cells that are resistant to bortezomib and may account for therapeutic failures in the clinic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • DNA-Binding Proteins / deficiency*
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics*
  • Proteasome Inhibitors / therapeutic use*
  • Regulatory Factor X Transcription Factors
  • Transcription Factors / deficiency*
  • X-Box Binding Protein 1

Substances

  • DNA-Binding Proteins
  • Proteasome Inhibitors
  • Regulatory Factor X Transcription Factors
  • Transcription Factors
  • X-Box Binding Protein 1
  • XBP1 protein, human